AMGN: EMA Revokes Tavneos
EMA recommends revoking marketing authorisation for AMGN's Tavneos due to risks outweighing benefits
AMGN EMA recommends revoking marketing authorisation for AMGN''s Tavneos.
Benefits no longer proven to outweigh risks of treatment.